To avoid anti-kickback litigation with government, pharma companies need a defensible position on FMV assessments
Stephen Rothenberg, Numerof & Associates, Inc.
Advertisement
Articles by Stephen Rothenberg, Numerof & Associates, Inc.
Advertisement
Latest Updated Articles
- Defending Fair Market Value (FMV) Assessments
Published: June 28th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
The Great Repricing: How Pharma Must Evolve for Three Diverging Payer Economies
2
The ROI Moment Pharma Keeps Missing: Point-of-Care as Revenue Protection
3
A 'Beautiful Fake': Pharma Fraudsters Upping Their Game
4
Trade & Channel Strategies 2025: The $405 Billion Patent Cliff Demands Partnership and Adaptive Market Access Strategies
5
